We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+1.67%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$929M
AUM Growth
-$261M
Cap. Flow
-$241M
Cap. Flow %
-25.92%
Top 10 Hldgs %
77.4%
Holding
34
New
2
Increased
4
Reduced
22
Closed
3

Top Buys

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$23.1M
2
URGN icon
UroGen Pharma
URGN
+$6.06M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.04M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$3.66M
5
CTMX icon
CytomX Therapeutics
CTMX
+$3.47M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$165M
2
IMCR icon
Immunocore
IMCR
+$22.3M
3
LEGN icon
Legend Biotech
LEGN
+$20.7M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.77M
5
LQDA icon
Liquidia Corp
LQDA
+$6.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSGN icon
26
Design Therapeutics
DSGN
$736M
$3.47M 0.37%
1,029,579
+125,562
+14% +$470K
PRQR icon
27
ProQR Therapeutics
PRQR
$243M
$3.36M 0.36%
1,649,462
-100,538
-6% -$164K
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.39B
$3.33M 0.36%
+253,979
New +$3.66M
BNR
29
Burning Rock Biotech
BNR
$3.14M 0.34%
994,883
– –
LQDA icon
30
Liquidia Corp
LQDA
$7.67B
$2.49M 0.27%
200,047
-433,755
-68% -$6.42M
CLYM
31
Climb Bio
CLYM
$735M
$1.28M 0.14%
1,028,341
-18,659
-2% -$23.2K
LEGN icon
32
Legend Biotech
LEGN
$4.3B
– –
-610,000
Closed -$20.7M
NTRA icon
33
Natera
NTRA
$37.5B
– –
-1,167,570
Closed -$165M
SLNO
34
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-302,500
Closed -$21.6M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Kynam Capital Management held 34 positions worth $929M, down 22% from $1.19B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Kynam Capital Management withdrew a net $241M in Q2 2025, closing 3 positions and reducing 22 holdings. Its most notable exit was Natera, an estimated $165M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Edgewise Therapeutics worth $3.33M.

  • Kynam Capital Management's largest Q2 2025 buy was Edgewise Therapeutics: 253,979 shares worth $3.33M.
  • Kynam Capital Management added most to Vera Therapeutics in Q2 2025, an estimated $23.1M increase.
  • Kynam Capital Management's biggest Q2 2025 reduction was Immunocore, cutting an estimated $22.3M.
  • Kynam Capital Management fully exited Natera in Q2 2025, selling an estimated $165M.
  • Kynam Capital Management's ten largest holdings make up 77% of its $929M portfolio in Q2 2025.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q2 2025.
  • Kynam Capital Management's portfolio value fell 22% quarter-over-quarter to $929M.

Based on Kynam Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.